Virta Study shows a Ketogenic Diet can Prevent Liver Disease - Interview MD Schur & PI MD Wolfberg 26m
Fatty liver disease (MASLD) is a major cause of liver disease and even liver failure. But many are surprised to learn it’s not primarily a liver problem. Growing evidence suggests the root issue may be metabolic dysfunction affecting the entire body, and that perspective can drastically change how we approach treating and preventing it.
In this interview, Dr. Bret Scher sits down with Dr. Adam Wolfberg to discuss a newly published study in Hepatology examining how a ketogenic intervention may help prevent metabolic liver disease before it progresses.
:::spoiler summerizer
**Metabolic dysfunction as one body-wide process**
- MAFLD/MASLD is common, preventable liver disease linked to metabolic dysfunction rather than alcohol or infection.
- Metabolic dysfunction affects the brain, liver, blood sugar, heart, kidneys, and the body as an interconnected system.
- Medicine is often too siloed, while liver disease, type 2 diabetes, obesity, cardiovascular disease, kidney disease, and behavioral conditions belong in the same metabolic map.
**Terminology and scale**
- NAFLD was the older term for fatty liver not caused by alcohol, and MASLD/MAFLD is the metabolic-dysfunction version.
- MASH is the more advanced inflammatory form, previously NASH, and it raises risk for cirrhosis and related hazards.
- The prevalence figures are 25% at the opening, then 25% to 34% for NAFLD/MASLD, around 80 to 90 million Americans, with NASH at 15 to 20 million.
**Why Virta studied liver outcomes**
- Virta began with a type 2 diabetes nutritional program built around low-carbohydrate/keto eating, coaching, clinician oversight, digital tools, and content.
- The earlier diabetes trial found disease reversal in a significant majority and later showed better liver tests without a liver-focused program.
- The original prospective work showed ALT down 3% and AST down 21%, so liver outcomes became a natural next question.
**Hepatology/Komodo study design**
- The new Hepatology paper used Komodo payer-record data and compared just over 5,000 Virta patients with an identically sized matched usual-care group.
- Matching used age, diagnoses, geography, and medications, while patient identities stayed hidden from the researchers.
- The study was not randomized; the major limitation was that the usual-care group was out in the wild, with unknown diet, exercise, or health behavior.
- The selection-bias issue matters, and the intervention still represents the kind of health behavior clinicians want patients to choose.
**Main liver outcomes**
- Any liver-related diagnosis was lower with Virta: about 27 versus almost 43 per 1,000 person-years.
- MASH-and-beyond or more advanced liver disease was also lower: 4.2 versus about 10 per 1,000 person-years.
- The NNT was 65 people per year to prevent any liver-related diagnosis, which was low for prevention.
- This was a prevention result, because the cohort was not mainly a liver-disease care cohort.
**Cost and payer incentives**
- The cost analysis was not at hand, but the Virta-side total cost of care was said to fall dramatically relative to matched controls, including the price of Virta.
- The American payment structure makes prevention hard because employers and health plans may hold financial responsibility for only two or three years.
- Virta therefore has to show economic value within one or two years, not only long-term health value.
**What drove the benefit**
- The study does not isolate coaching, keto, weight loss, cleaner eating, or the whole Virta system as the exact driver.
- More weight loss lined up with greater liver benefit.
- Beta-hydroxybutyrate levels did not separate higher-benefit from lower-benefit groups, so deeper nutritional ketosis was not required for the liver signal.
- For brain-focused metabolic work, higher ketones matter more; for general metabolic health, liver prevention, weight loss, and type 2 diabetes, lower ketone levels can still be enough.
**Mediterranean diet comparison**
- Search results and clinical guidance often point people toward the Mediterranean diet for fatty liver or MASLD.
- The Mediterranean-diet literature was mixed, with some studies showing reduced liver-disease risk and others not showing it.
- One cited Mediterranean-diet study was criticized as clinic-based adherence measurement with healthy-user and selection bias.
- The keto/Virta prevention study warrants comparable attention when Mediterranean observational work is used as diet evidence.
**Clinician takeaway**
- The expensive medication pathway now includes Wegovy/semaglutide for obesity plus liver disease at approximately F2/F3 disease.
- The goal is to keep patients from reaching that stage by using accessible low-carbohydrate nutrition earlier.
- A well-formulated ketogenic diet is low carb, not zero carb, and people can move into it gradually.
- Doctors do not need to personally deliver every diet detail, because content, coaching programs, and employer or health-plan access can carry much of that burden.
**Closing synthesis**
- The notable result was the NNT of 65 to prevent one serious liver complication.
- The health signal matters more than the cost signal because liver disease is serious yet preventable.
- The study grew from type 2 diabetes care, liver-test improvements, and then a larger prevention question.
- Metabolic health touches the brain and body together, so improving it can affect many organ systems at once.
References
- [00:00] Reduced risk of liver-related events among patients receiving individualized nutrition-focused remote care in the United States — https://doi.org/10.1097/HEP.0000000000001713
- [04:00] A Novel Intervention Including Individualized Nutritional Recommendations Reduces Hemoglobin A1c Level, Medication Use, and Weight in Type 2 Diabetes — https://doi.org/10.2196/diabetes.6981
- [06:00] Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study — https://doi.org/10.1136/bmjopen-2018-023597
- [19:00] Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance — https://doi.org/10.1038/ajg.2017.371
- [21:00] FDA Approves Treatment for Serious Liver Disease Known as MASH — https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash
:::
In this interview, Dr. Bret Scher sits down with Dr. Adam Wolfberg to discuss a newly published study in Hepatology examining how a ketogenic intervention may help prevent metabolic liver disease before it progresses.
:::spoiler summerizer
**Metabolic dysfunction as one body-wide process**
- MAFLD/MASLD is common, preventable liver disease linked to metabolic dysfunction rather than alcohol or infection.
- Metabolic dysfunction affects the brain, liver, blood sugar, heart, kidneys, and the body as an interconnected system.
- Medicine is often too siloed, while liver disease, type 2 diabetes, obesity, cardiovascular disease, kidney disease, and behavioral conditions belong in the same metabolic map.
**Terminology and scale**
- NAFLD was the older term for fatty liver not caused by alcohol, and MASLD/MAFLD is the metabolic-dysfunction version.
- MASH is the more advanced inflammatory form, previously NASH, and it raises risk for cirrhosis and related hazards.
- The prevalence figures are 25% at the opening, then 25% to 34% for NAFLD/MASLD, around 80 to 90 million Americans, with NASH at 15 to 20 million.
**Why Virta studied liver outcomes**
- Virta began with a type 2 diabetes nutritional program built around low-carbohydrate/keto eating, coaching, clinician oversight, digital tools, and content.
- The earlier diabetes trial found disease reversal in a significant majority and later showed better liver tests without a liver-focused program.
- The original prospective work showed ALT down 3% and AST down 21%, so liver outcomes became a natural next question.
**Hepatology/Komodo study design**
- The new Hepatology paper used Komodo payer-record data and compared just over 5,000 Virta patients with an identically sized matched usual-care group.
- Matching used age, diagnoses, geography, and medications, while patient identities stayed hidden from the researchers.
- The study was not randomized; the major limitation was that the usual-care group was out in the wild, with unknown diet, exercise, or health behavior.
- The selection-bias issue matters, and the intervention still represents the kind of health behavior clinicians want patients to choose.
**Main liver outcomes**
- Any liver-related diagnosis was lower with Virta: about 27 versus almost 43 per 1,000 person-years.
- MASH-and-beyond or more advanced liver disease was also lower: 4.2 versus about 10 per 1,000 person-years.
- The NNT was 65 people per year to prevent any liver-related diagnosis, which was low for prevention.
- This was a prevention result, because the cohort was not mainly a liver-disease care cohort.
**Cost and payer incentives**
- The cost analysis was not at hand, but the Virta-side total cost of care was said to fall dramatically relative to matched controls, including the price of Virta.
- The American payment structure makes prevention hard because employers and health plans may hold financial responsibility for only two or three years.
- Virta therefore has to show economic value within one or two years, not only long-term health value.
**What drove the benefit**
- The study does not isolate coaching, keto, weight loss, cleaner eating, or the whole Virta system as the exact driver.
- More weight loss lined up with greater liver benefit.
- Beta-hydroxybutyrate levels did not separate higher-benefit from lower-benefit groups, so deeper nutritional ketosis was not required for the liver signal.
- For brain-focused metabolic work, higher ketones matter more; for general metabolic health, liver prevention, weight loss, and type 2 diabetes, lower ketone levels can still be enough.
**Mediterranean diet comparison**
- Search results and clinical guidance often point people toward the Mediterranean diet for fatty liver or MASLD.
- The Mediterranean-diet literature was mixed, with some studies showing reduced liver-disease risk and others not showing it.
- One cited Mediterranean-diet study was criticized as clinic-based adherence measurement with healthy-user and selection bias.
- The keto/Virta prevention study warrants comparable attention when Mediterranean observational work is used as diet evidence.
**Clinician takeaway**
- The expensive medication pathway now includes Wegovy/semaglutide for obesity plus liver disease at approximately F2/F3 disease.
- The goal is to keep patients from reaching that stage by using accessible low-carbohydrate nutrition earlier.
- A well-formulated ketogenic diet is low carb, not zero carb, and people can move into it gradually.
- Doctors do not need to personally deliver every diet detail, because content, coaching programs, and employer or health-plan access can carry much of that burden.
**Closing synthesis**
- The notable result was the NNT of 65 to prevent one serious liver complication.
- The health signal matters more than the cost signal because liver disease is serious yet preventable.
- The study grew from type 2 diabetes care, liver-test improvements, and then a larger prevention question.
- Metabolic health touches the brain and body together, so improving it can affect many organ systems at once.
References
- [00:00] Reduced risk of liver-related events among patients receiving individualized nutrition-focused remote care in the United States — https://doi.org/10.1097/HEP.0000000000001713
- [04:00] A Novel Intervention Including Individualized Nutritional Recommendations Reduces Hemoglobin A1c Level, Medication Use, and Weight in Type 2 Diabetes — https://doi.org/10.2196/diabetes.6981
- [06:00] Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study — https://doi.org/10.1136/bmjopen-2018-023597
- [19:00] Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance — https://doi.org/10.1038/ajg.2017.371
- [21:00] FDA Approves Treatment for Serious Liver Disease Known as MASH — https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash
:::